TRUCE-02: An open label, single-arm, phase II study of tislelizumab combined with nab-paclitaxel for high-risk non-muscle-invasive urothelial bladder carcinoma.

Abstract

4507 Background: Pts with multiple or tumors with large invasion areas which are un-completely-resectable through TURBT would be recommended radical cystectomy in the clinical treatment. The KEYNOTE-057 study has illuminated the efficiency of immune checkpoint inhibitors monotherapy in HR-NMIBC pts, with acceptable adverse events (AEs). However, the role of PD-1/PD-L1 inhibitor in combination with chemotherapy in NMIBC pts remains unclear. We report preliminary treatment efficiency, safety data, and exploratory work of TRUCE-02 trial. Methods: TRUCE-02 is a phase II study for NMIBC pts with uncompletely resectable tumour by TURBT. The primary endpoint was complete response(absence of non-muscle-invasive bladder cancer or progressive disease). Pts that meet the criteria would receive tislelizumab 200mg on days 1 plus paclitaxel 200mg on days 2 every 3 weeks (Q3W) x 3 or 4 cycles followed by a comprehensive assessment including pathology, urine cytology, and imageology. Meanwhile, biomarker analyses included programmed death-ligand 1 (PD-L1) expression using the combined positive score (CPS; Dako 22C3 pharmDx assay) and whole transcriptome RNA sequencing of the tumor. Results: Between July 2020 and January 2022, 54 pts were enrolled. 42 pts have completed whole 3 or 4 treatment cycles and reached the primary endpoint. 23 pts achieved CR condition (56%, 95%CI, 43.6% and 74.4%). ORR of 60% (N=25/42, 95%CI, 45.2% and 74.8%). As a secondary endpoint, 33 pts remain cystectomy-free condition (78.6%, 95%CI, 66.2% and 91%). Grade 3-4 AEs were lower than 2%. Urine cytology showed its diagnostic efficiency of 68.42% (95%CI, 61.3% and 75.6%), urine FISH showed a diagnostic efficiency of 45.71% (95%CI, 37.7% and 53.4%) before pathological assessment. As for PD-L1 expression, 47.3% (N = 9/19) of response pts (CR+PR) showed positive, 50% (N = 5/10) of un-response pts (PD+SD) showed positive. We also found out through sequencing results that AR, TCF7L2 might be underlying markers that predict adverse outcomes for pts in this crew. HRR mutation may predict a positive prognosis and mutations in NMIBC which might predict the prognosis of this treatment plan. Conclusions: Tislelizumab with nab-paclitaxel represents a novel treatment option with a satisfactory benefit in treating NMIBC. PD-L1 expression has no obvious correlation with the efficiency of this treatment plan. WGS result also showed that there are mutation markers that may predict whether pts would benefit from this treatment plan. Clinical trial information: NCT04730232. [Table: see text]

The addition of tislelizumab to gemcitabine and cisplatin chemotherapy increases thrombocytopenia in patients with urothelial carcinoma: A single‐center study based on propensity score matching

“…The results showed that, compared with the NAC and neoadjuvant immunotherapy cohorts, patients treated with neoadjuvant T + GC achieved a significantly higher complete response rate ( p = 0.001) and pathological downstaging rate ( p = 0.007). In addition, a series of TRUCE studies were designed to evaluate the efficacy and safety of neoadjuvant tislelizumab in combination with nab‐paclitaxel in both MIBC 21 and high‐risk non‐muscle‐invasive urothelial bladder carcinoma (NMIBC) 22 . Researchers have found that the combination of tislelizumab and nab‐paclitaxel provides a novel neoadjuvant therapeutic option with a satisfactory efficacy and safety profile 21 .…”

“…In addition, a series of TRUCE studies were designed to evaluate the efficacy and safety of neoadjuvant tislelizumab in combination with nab‐paclitaxel in both MIBC 21 and high‐risk non‐muscle‐invasive urothelial bladder carcinoma (NMIBC). 22 Researchers have found that the combination of tislelizumab and nab‐paclitaxel provides a novel neoadjuvant therapeutic option with a satisfactory efficacy and safety profile. 21 Another retrospective study was performed to assess the efficacy of T + GC as a first‐line adjuvant treatment in patients with locally advanced or metastatic BC.…”

2022 American Society of Clinical Oncology (ASCO): Meeting highlights

“…The primary endpoint, CR rate, was 55% at nine months. 12 The combined toxicity of two systemic drugs makes this combination unlikely to undergo further investigation in North America or Europe. Results of the CORE1 trial, however, have generated excitement in the NMIBC field.…”